Key Takeaways
- High-margin biologics and drug-device combinations drove EBITDA margin to 36%, validating the strategic pivot toward complex, sticky manufacturing.
- Revenue grew 18% to ~INR400 crores in Q3, crossing INR1,000 crores YTD, fueled by long-term contract wins and customer trust in the CDMO platform.
- GLP-1 capacity is expanding 5x to 22 crore units, backed by customer co-investment and binding forecasts, but FY26 revenue recognition will be back-half loaded and inherently ambiguous.
- The balance sheet is being rapidly deleveraged: half the INR801 crore fundraise retired high-cost debt, with a target to be debt-free before FY27 end.
- What to watch next quarter: concrete plans for balance sheet optimization (goodwill/intangible), the pace of biologics customer conversion, and any early signals on FY26 commercial supply volumes.
GLP-1: The Core Growth Engine
- Market context is supply-constrained, not demand-constrained: IQVIA reports ~50 crore total GLP-1 units globally, but NOVO has focused almost entirely on the US and Europe, leaving massive populations in Brazil, India and China completely unserved.
- 20 active GLP-1 customers represent the "who's who of the global generic space," with volumes for Liraglutide increasing nicely and management more excited about Ozempic and Wegovy.
- Customer forecasts have been revised upward multiple times, giving confidence to invest in capacity; customers access it via capex participation, reservation fees, or binding 12-18 month take-or-pay commitments within 24-36 month forecasts.
- Revenue mix is shifting from MSA to CSA: FY25 is predominantly pre-approval revenue; FY26 is a cusp year evolving toward commercial sales, with a steady-state target of 80% CSA.
- FY26 will be "a little bit ambiguous" on exact sellable volume: the existing 4 crore units can be sold 100%, but how much of the 9 crore capacity coming online gets absorbed is uncertain, so guidance is "guarded, not low ball, not irrationally exuberant."
- Competitive moat is time itself: a competitor starting today would need 24-36 months for a filling line, 6 months for data generation, 6 months for FDA approval, and another year for product approval, meaning the first revenue dollar arrives in 5 years.
Neeraj Sharma: "Today you invest, the first revenue dollar comes back in 5 years. And by the time, as I said, we as pioneers have a significant headstart."
Biologics & Drug-Device: The Margin Story
- The 36% EBITDA margin is structural, driven by increasing traction in biologics and drug-device combination businesses that operate at very high margins.
- Integrated drug substance and drug product on one site is a rare global capability; the real niche is in the microbial area, where the company can develop, supply clinical trial quantities, and manufacture commercial volumes.
- First innovator customer onboarded in microbial biologics: a new biological entity, first in class, taken at Phase 3. Customer acquisition cycles are 12-24 months, but once onboarded, "you have a customer almost for life."
- 7 actual or potential NCE-1 programs including GLP are in the pipeline, with contract structures combining low manufacturing pricing plus profit-share upside.
- Soft gelatine capacity has been increased, making the company among global leaders; the new capacity is already spoken for by new CDMO customers.
Capacity & Capex: Scaling for the Opportunity
- Capacity is expanding 5x from ~4 crore to ~22 crore units over the next 3-4 years, with INR10 crore in capex planned over 2-4 years, heavily weighted toward drug-device combination capabilities.
- Customer risk-sharing de-risks the buildout: partners participate in capex or pay reservation fees, so the expansion can be funded from internal accruals without borrowing.
- Funding is split: half from the capital raise, balance from cash generation and customer participation.
- Market share ambition is 15-20% of the cartridge fill-and-finish segment, potentially rising to about a third of the total generic market once all markets are out, though the timing of that steady state is uncertain.
- Additional capacities for Europe and the US are being planned, with management noting they "have the luxury of time" on those decisions.
Arun Kumar: "We play the risk along with our partners jointly in the sense that we expect our partners to participate in capex or in reservation capacity fee. Consequently, we have that ability to take those decisions and that is why Anurag has articulated that capex should be from internal accruals because we don't need to borrow to build these capexes."
Financial Position & Balance Sheet
- INR801 crore was raised during the quarter; half was used to retire high-cost, complicated guarantee-backed debt, significantly reducing guarantees and interest costs, with interest expected to halve.
- Debt-free target is before FY27 end, with a healthy medium-to-long-term debt-to-EBITDA ratio anticipated at less than one.
- Normalized PAT excludes one-time exceptional items, interest on discontinued debt, and scheme-related amortization, which are not reflective of operating performance.
- Balance sheet optimization is under evaluation: management is engaged with advisors and tax experts to address the large goodwill and intangible from restructuring, looking at comparable international situations, with more concrete solutions promised for the next call.
- Operating leverage is strong: EBITDA growth is outpacing revenue growth as the business scales.
Commercial Model & Customer Dynamics
- 60-plus logos span all service offerings, with many customers common across multiple services, creating cross-sell stickiness.
- More MSA contracts were signed in Q3 than in all of FY24, reflecting accelerating customer acquisition ahead of the commercial supply wave.
- Client concentration is not a concern: 20 active GLP-1 customers is considered a broad base, though management acknowledges not all will secure approvals.
- Contract structures blend downside protection with upside: pure manufacturing activity carries a healthy minimum EBITDA target, while profit-share arrangements on partnered NCE-1 programs provide additional value streams.
- Seasonality is a near-term phenomenon: from FY27 onward, 80% of volumes will be predictable CSA revenue; the current top-sided H2 guidance reflects the timing of commercial supply commencements.
Neeraj Sharma: "I call it a fool's errand if I were to forecast where this market would be the way it is growing."
Operational Milestones & Governance
- Successfully listed on BSE and NSE after receiving NCLT approvals, completing the restructuring process.
- USFDA issued an EIR for the penicillin site in Bangalore, clearing a regulatory milestone.
- 36 successful audits were completed in 2024 from both regulatory bodies and customers, underscoring quality compliance.
- A highly accomplished board is being assembled, with announcements expected soon.
- An Investor Day is planned for Mumbai, scheduled for end of February or early March.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | 25% to 30% growth | Medium term (3-4 years) |
| Revenue scale | INR40 crore company | Next 3-4 years |
| EBITDA margin | 40% | Medium term (implied 3-4 years) |
| FY26 EBITDA margin | Within the range reported in Q3 FY25 | FY26 |
| Capacity expansion | 5x increase from ~4 crore to ~22 crore units | Next 3-4 years |
| Capex investment | INR10 crore | Next 2-4 years |
| Debt-free | Zero debt | Before end of FY27 |
| Debt-to-EBITDA | Less than 1x | Medium to long term |
| Revenue mix | 80% CSA, 20% MSA | Steady state (post-FY26) |
| Biologics commercialization | First revenue from current Phase 3 asset | 3-4 years out |
| Balance sheet optimization plan | Concrete solutions presented | Next earnings call |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹392.6 cr, growth of about 18% |
| EBITDA | ₹143.2 cr, more than the previous two quarters combined |
| EBITDA margin | 36% |
| 9-month revenue | a little over ₹1,000 cr |
| 9-month EBITDA | about ₹284 cr |
| Normalized EPS (fully diluted) | ₹7.8 |
| Return on capital employed | mid-30s range |
| Net debt | ₹581.7 cr, net of deposits and cash equivalents |
| Fundraise during the quarter | ₹801 cr, half used to retire high-cost debt |
| Medium-term revenue growth guidance | 25% to 30% CAGR |
| Medium-term revenue target | ₹40 cr revenue company in the next 3 to 4 years |
| Medium-term EBITDA margin target | 40% |
| Planned capex | $100 million over the next 2 to 4 years |
| GLP-1 customers | 20 |
| Total customers (logos) | 60-plus across all service offerings |
| GLP-1 cartridge capacity expansion | 5x, from 4 crore to almost 22 crore units in the next 3 to 4 years |
| MSA contracts signed in Q3 | more than in the full year FY24 |
| Successful audits in 2024 | 36 |